Transparency Market Research

High Incidence of Diseases Drives Antisense and RNAi Therapeutics Market

Transparency Market Research Report Added "Antisense and RNAi Therapeutics Market" to its database.


Albany, NY -- (SBWIRE) -- 03/08/2016 -- Transparency Market Research presents a research report that discusses the antisense and RNAi therapeutics market in complete detail. The research report, titled "Antisense and RNAi Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023," provides a comprehensive overview of the overall antisense and RNAi therapeutics market, explaining in detail the impact of growing investments and the supportive regulatory framework. Additionally, the research report also uses SWOT analysis to evaluate the strengths, weaknesses, opportunities, and threats. To provide a fair understanding of the threat of new entrants, the threat of substitute products or services, the bargaining power of customers, the bargaining power of suppliers, and the intensity of competitive rivalry, the research report has used Porter's five forces analysis.

The global antisense and RNAi therapeutics market report studies two very important technologies, namely antisense and RNAi technologies. Antisense therapeutics are a type of treatment offered to those who are suffering from chronic infections or genetic disorders. This therapy synthesizes a strand of nucleic acid such as RNA, DNA, or a chemical analogue, which binds to the mRNA produced by the problematic gene to make it inactive. On the other hand, RNAi therapeutics focus on treating diseases such as cancer and neurodegenerative diseases. The several advantages of these technologies are the main reason for their increasing application in several research institutes and pharmaceutical companies.

Download PDF:

The global antisense and RNAi therapeutics market is segmented on the basis of technology and therapeutic applications. The RNAi technology segment is inclusive of siRNA and miRNA. Meanwhile, the therapeutics segment is further divided into respiratory disorders, ocular diseases, kidney diseases, neurodegenerative diseases, infectious diseases, lung disorders, cancer, and genetic disorders. Some of the biggest end users in the global antisense and RNAi therapeutics market are the pharmaceutical industry and therapeutics and research institutes.

The research report suggests that the infectious diseases sub-segment is anticipated to witness a good growth rate in the coming years due to the high incidence of infectious diseases such as AIDS. Furthermore, the growing number of cases of cardiac diseases, neurodegenerative diseases, and coronary artery diseases is also fueling this market.

Some of the players in the global antisense and RNAi therapeutics market are Alnylam Pharmaceuticals Inc., Dainippon SumitomoPharma, Sanofi S.A., Isis Pharmaceuticals, AstraZeneca plc, Tekmira Pharmaceuticals Corporation, Allergan, Inc., Antisense Therapeutics, Biogen Idec, Ascletis Innovation, Atlantic Pharmaceuticals Inc., Bristol-Myers Squibb, Pfizer, Inc., GlaxoSmithKline plc, and Novartis AG. The research report gives an insight into the competitive landscape prevalent in the global antisense and RNAi therapeutics market. Furthermore, it assesses the financial overview, research and development activities, product portfolio, investment outlook, and strategic mergers and acquisitions of the top players in the market.

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453